Table 1.

Compilation of phase II trials of cytotoxic drugs in GBM^a

Agent	N Patients	Response Criteria	ORR, %	PFS-6, %
NABTC119	437	Macdonald	7	16
Carboplatin + thymidine120	45	Macdonald	2.2	Not stated
BCNU121	40	Macdonald	15	17.5
BCNU + TMZ122	36	Macdonald	5.5	21
Carboplatin + erlotinib123	43	Macdonald	2.3	14
CCNU124,125	157	Levin or RANO	4–9	19–25
CCNU + cloretazine125	32	Macdonald	0	6
Hydroxyurea +/− imatinib126	120	Macdonald	0.8	5
Irinotecan127,128	128	Macdonald	0–17	NR
PCV129,130	146	Macdonald	4–11	32–38
Procarbazine131	113	Macdonald	5.3	8
TMZ (5/28)131,132	240	Macdonald	5–8	18–21
TMZ (7/7)133	45	Macdonald	15.5	43.8
TMZ (21/28)134,135	91	Macdonald	9–13	11–30
TMZ (28/28)–PD off TMZ136	29	Macdonald	11.1	35.7
TMZ + thalidomide137	43	Macdonald	7	24

Abbreviations: TMZ, temozolomide; NABTC, North American brain tumor consortium.

^aThe case number–weighted mean ORR and PFS-6 for these studies is 6% and 17%, respectively.